Beyond Orkambi: Cystic Fibrosis Pipeline Includes Other Genetic, Symptomatic Therapy Approaches

PTC Therapeutics looks to offer drug therapy for nonsense mutation CF patients, while Corbus is developing an anti-inflammatory, antifibrotic drug that it hopes will benefit the entire CF patient population.